Eli Lilly Claims 30 Percent of Oral Obesity Market
Eli Lilly announced it captured over thirty percent of new US oral obesity drug patients. The milestone narrows the early lead held by rival Novo Nordisk. Investors continue monitoring demand for oral treatments.
Insights:
Eli Lilly captured over 30% of new patients in the United States oral obesity treatment market on Monday, narrowing the early lead held by rival therapies. The shift intensifies competition in the oral weight-loss sector, which targets patients reluctant to use injections. Oral treatments could comprise more than a third of GLP-1 weight-loss therapy use by 2030, according to industry projections.
